Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of Ninerafaxstat In Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM
Rochester, MN
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM
-
An Open-Label Study Of CK-3773274 For Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM)
Scottsdale/Phoenix, AZ
The purpose of this study is to collect long-term safety and tolerability data for aficamten (CK-3773274).
-
HCMR.2-Hypertrophic Cardiomyopathy Registry ( HCMR.2)
Rochester, MN
The purpose of this study is to refine identification of the clinical, imaging, biomarker and genetic variables that predict risk of the primary adverse clinical outcomes in HCM.
Contact Us for the Latest Status
-
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study To Evaluate The Efficacy And Safety Of SOtaglifloziN In SymptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)
Scottsdale/Phoenix, AZ
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
-
HCMR Re-Imaging Study
Rochester, MN
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system.
This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.
Closed for Enrollment
-
A Phase 3, Multi-Center, Randomized, Double-Blind Trial To Evaluate The Efficacy And Safety Of Aficamten Compared To Placebo In Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Rochester, MN
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
-
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial To Evaluate The Efficacy And Safety Of CK-3773274 In Adults With Symptomatic Hypertrophic Cardiomyopathy And Left Ventricular Outflow Tract Obstruction
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the effectiveness and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction.
-
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy (HCM ILR)
Rochester, MN
The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea.
-
A Randomized, Double-blind, Placebo-controlled Clinical Study To Evaluate Mavacamten In Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
-
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study To Evaluate The Efficacy And Safety Of SOtaglifloziN In SymptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)
Jacksonville, FL
Rochester, MN
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
-
An Open-Label Study Of CK-3773274 For Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM)
Jacksonville, FL
Rochester, MN
The purpose of this study is to collect long-term safety and tolerability data for aficamten (CK-3773274).
-
Hypertrophic Cardiomyopathy Clinical Survey
Rochester, MN
The purpose of this study is to use a survey to collect updated information on the clinical status of patients who have hypertrophic cardiomyopathy and are part of the ongoing database at Mayo Clinic.
-
The Relationship of Septal Pathology to Biomarkers in Hypertrophic Cardiomyopathy (SPIHCM)
Rochester, MN
Previous work has shown that high sensitivity troponin levels are associated with degree of septal hypertrophy in hypertrophic cardiomyopathy. To further evaluate for the mechanisms of this association, we plan to reavaluate the septal pathology from myectomies in patients with HCM. Our hypothesis is that high sensitivity troponin (hs-TnT) and other biomarkers including NT-pro BNP will correlate with septal pathology in hypertrophic cardiomyopathy (HCM).
-
Utility of Pre-Myectomy Coronary Angiography in Hypertrophic Cardiomyopathy
Rochester, MN
The purpose of this study is to assess patients with hypertrophic cardiomyopathy (HCM) undergoing first time sternotomy for septal myectomy without known coronary artery disease (CAD).
-
VALOR-HCM Trial: Mavacamten In HCM Patients Referred For SRT
Rochester, MN
The purpose of this study is to evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) and/or European Society of Cardiology (ESC) guidelines (i.e., guideline).
.